NASDAQ$KNSA
Kiniksa Pharmaceuticals Ltd · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Kiniksa reported its second quarter 2020 financial results and highlighted recent pipeline and corporate activity.
Kiniksa had a successful first half of 2020, with positive results from studies of rilonacept and vixarelimab, as well as mavrilimumab data published in The Lancet Rheumatology. The company is planning to submit an sBLA to the FDA for rilonacept in recurrent pericarditis this year. Evaluations of mavrilimumab and vixarelimab are progressing, and data is expected in the fourth quarter from the mavrilimumab GCA trial and the KPL-404 program. Recent capital raises and financial discipline are expected to extend the company's cash runway into 2023.
- Statistically significant results from the pivotal Phase 3 study of rilonacept in recurrent pericarditis.
- Positive results from the Phase 2a study of vixarelimab in prurigo nodularis.
- COVID-19 mavrilimumab data published in The Lancet Rheumatology.
- sBLA submission to the FDA for rilonacept in recurrent pericarditis planned for this year.
Headline financials
Revenue & EPS history
Kiniksa · Revenue · Quarterly
$214M
Revenue by segment
Kiniksa · $64.8M total across 1 segment · Q3 2023
- ARCALYST$64.8M+94.0%100.0%
Forward guidance
Kiniksa expects a catalyst-filled second half of the year with multiple data readouts and a planned sBLA submission.
Tailwinds
- Potential to bring rilonacept as a potential treatment option for patients with recurrent pericarditis
- Planned clinical trials and timing thereof, including a potential dose-ranging Phase 2b clinical trial of vixarelimab in prurigo nodularis
- Planned clinical trials and timing thereof, including a Phase 2 trial evaluating the investigational combination of Yescarta® (axicabtagene ciloleucel) and mavrilimumab in relapsed or refractory large B-cell lymphoma
- Projected timeframe for funding our current operating plan with current cash, cash equivalents and short-term investments
- Advancement of clinical-stage product candidates, rilonacept, mavrilimumab, vixarelimab and KPL-404
Headwinds
- Potential delays or difficulty in enrollment of patients in, and activation or continuation of sites for, our clinical trials
- Potential complications in coordinating among requirements, regulations and guidelines of regulatory authorities across a number of jurisdictions for our global clinical trials
- Potential amendments to our clinical trial protocols initiated by us or required by regulatory authorities
- Potential delays or difficulty in completing our clinical trials, including as a result of the COVID-19 pandemic
- Potential for low accrual of events in our clinical trials
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
+5.3%
Avg return
Earnings day
+5.2%
Avg return
5 days after
+7.8%
Avg return
30 days after
55%
17 / 31 earnings
Positive
+45.8%
Q3 2021
Best reaction
-16.6%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +23.5% | +26.7% | +16.6% | |
| Q4 2025 | -4.7% | -6.1% | -1.3% | |
| Q3 2025 | -2.9% | -8.8% | +4.8% | |
| Q1 2025 | +20.5% | +28.8% | +26.6% | |
| Q4 2024 | +0.5% | +3.3% | +19.0% | |
| Q3 2024 | -16.6% | -18.5% | -19.1% | |
| Q2 2024 | +17.8% | +22.1% | +22.5% | |
| Q1 2024 | +4.4% | +4.6% | +12.1% | |
| Q4 2023 | +1.2% | -3.4% | -5.6% | |
| Q3 2023 | -3.4% | +3.3% | +3.1% | |
| Q2 2023 | +35.2% | +26.8% | +18.1% | |
| Q1 2023 | +24.2% | +24.7% | +29.0% | |
| Q4 2022 | -5.6% | -7.8% | -19.7% | |
| Q3 2022 | +8.6% | +21.7% | +49.3% | |
| Q2 2022 | +17.3% | +29.9% | +14.7% | |
| Q1 2022 | +5.1% | -6.8% | -18.4% | |
| Q4 2021 | -6.8% | -3.4% | -7.2% | |
| Q3 2021 | +45.8% | +41.8% | +8.8% | |
| Q2 2021 | -1.4% | -5.4% | -10.0% | |
| Q1 2021 | -9.0% | -11.4% | -19.4% | |
| Q4 2020 | -6.3% | -11.9% | -28.5% | |
| Q3 2020 | -5.9% | -7.2% | +9.6% | |
| Q2 2020 | +0.8% | -1.2% | -14.7% | |
| Q1 2020 | -7.0% | -9.2% | -0.6% | |
| Q4 2019 | -0.7% | +6.1% | -29.5% | |
| Q3 2019 | +15.7% | +24.5% | +80.8% | |
| Q2 2019 | -2.4% | -12.1% | -9.4% | |
| Q1 2019 | +8.2% | +2.6% | +6.5% | |
| Q4 2018 | -6.1% | -0.2% | +20.2% | |
| Q3 2018 | +11.9% | +5.1% | +6.2% | |
| Q2 2018 | +1.7% | +3.5% | +78.2% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro